Covalon Technologies (TSXV:COV) announced today that it appointed Brent Ashton as its new CEO and as a board director.
Ashton’s appointment goes into effect immediately. The medtech industry veteran has experience leading large business units for wound care, vascular access, infection prevention and diagnostics. His track record includes time spent at large medtech companies like 3M and BD.
Covalon develops technologies and solutions for advanced wound care, infection prevention, and medical device coatings. The company believes that, with his broad experience, Ashton can lead the company into its next phase of growth and development.
Board Chair Amir Boloor has served as interim CEO since September when former CEO Brian Pedlar departed the corner office.
“On behalf of the board, I am delighted to welcome Mr. Brent Ashton to Covalon as its new CEO,” Boloor said. “Brent’s extensive medtech industry expertise specifically as it relates to our products and end-markets as well as his strategic leadership and demonstrated track record of driving both top and bottom-line growth will play a crucial part in fast-tracking Covalon’s growth journey. As we remain committed to fortifying our operations and prioritizing both profitability and sustained growth, Brent’s valuable contributions will be instrumental in achieving our strategic objectives.”
Ashton brings more than 25 years of experience, most recently serving as VP and GM of BD’s Specimen Management group. Before his time at BD, Ashton spent 13 years at 3M Health Care, with his posts including global business director and business unit VP. Ashton’s most recent position at 3M involved leading commercial efforts for the patient preparation and management unit.
“I am extremely excited about the opportunity to lead Covalon and its talented and dedicated team to further success,” Ashton said. “Covalon has exceptional, compassionate medical products that make a real difference to patients and the clinicians who treat them. As CEO, I look forward to meeting the needs of our prestigious customers and supporting our team as we deliver on our strategic priorities and drive both long-term growth and value creation for our shareholders.”
